会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
    • 甲氧基-1,3,5-三嗪衍生物和含有它们的药物组合物
    • KR1020020076920A
    • 2002-10-11
    • KR1020010017143
    • 2001-03-31
    • 동화약품주식회사
    • 정용호이치우양왕용이학동박휘정장윤영이진수
    • C07D413/14
    • C07D403/14C07D401/14C07D403/12C07D413/14
    • PURPOSE: Provided are a methoxy-1,3,5-triazine derivative which inhibit the growth of Hepatitis C virus(HCV) and a pharmaceutical composition containing the same, therefore it can be useful for the prevention and treatment of hepatitis type B and hepatitis type C. CONSTITUTION: The methoxy-1,3,5-triazine derivative is represented by formula(1) and its pharmaceutically acceptable salt are provided. In the formula(1), R1 is H or C1-C8 alkyl; R2 is H, hydroxy, C1-C4 linear or branched chain alkyl, C1-C3 linear or branched chain alkoxy, C1-C3 hydroxyalkyl, C2-C6 dialkylamino, C3-C6 cycloalkyl, lactam, saturated or unsaturated 5 or 6 atom hetero ring compound optionally substituted with C1-C3 linear or branched chain alkyl substituted or unsubstituted, and containing one or two hetero atom selected from N, O and S; or bicyclo compound containing one or two hetero atom selected from N, O and S; n is an integer of 0 to 4; and R3 is 5-indazolyl or 6-indazolyl. The method for producing the methoxy-1,3,5-triazine derivative comprises the steps of: reacting 2,4-dichloro-6-methoxy-1,3,5-triazine of formula(4) with 5-aminoindazole or 6-aminoindazole of formula(5) in the presence of base to prepare aminoindazole substituted 2-chloro-6-methoxy-1,3,5-triazine derivative of formula(6); and reacting the compound of formula(6) with amine compound of formula(7) in the presence of amine to prepare methoxy-1,3,5-triazine derivative of formula(1).
    • 目的:提供抑制丙型肝炎病毒(HCV)生长的甲氧基-1,3,5-三嗪衍生物和含有该丙氨酸病毒(HCV)的药物组合物,因此可用于预防和治疗乙型肝炎和肝炎 C型。构成:提供甲氧基-1,3,5-三嗪衍生物由式(1)表示,并提供其药学上可接受的盐。 在式(1)中,R 1是H或C 1 -C 8烷基; R2是H,羟基,C1-C4直链或支链烷基,C1-C3直链或支链烷氧基,C1-C3羟基烷基,C2-C6二烷基氨基,C3-C6环烷基,内酰胺,饱和或不饱和的5或6原子杂环 任选被取代或未取代的C 1 -C 3直链或支链烷基取代的,含有一个或两个选自N,O和S的杂原子的化合物; 或含有一个或两个选自N,O和S的杂原子的双环化合物; n为0〜4的整数。 并且R 3是5-吲唑基或6-吲唑基。 制备甲氧基-1,3,5-三嗪衍生物的方法包括以下步骤:使式(4)的2,4-二氯-6-甲氧基-1,3,5-三嗪与5-氨基吲唑或6- 式(5)的氨基吲唑在碱的存在下反应,制备式(6)的氨基吲唑取代的2-氯-6-甲氧基-1,3,5-三嗪衍生物; 并在胺的存在下使式(6)的化合物与式(7)的胺化合物反应,制得式(1)的甲氧基-1,3,5-三嗪衍生物。
    • 5. 发明公开
    • 신규의 2,4-디플루오로벤즈아미드 유도체
    • 新的2,4-二氟硼酸衍生物
    • KR1020030001167A
    • 2003-01-06
    • KR1020010037547
    • 2001-06-28
    • 동화약품주식회사
    • 정용호이치우양왕용이학동박휘정장윤영이진수
    • C07D401/12
    • C07D249/08C07D231/12C07D231/56C07D233/56C07D401/12C07D403/12
    • PURPOSE: Provided are novel 2,4-difluorobenzamide derivatives which are excellent in inhibition of the growth of both HBV and HCV, and thus used as prevention and treatment agents for HBV hepatitis and HCV hepatitis. also, provided are their pharmaceutically acceptable salts and their manufacturing method. CONSTITUTION: The 2,4-difluorobenzamide derivative is represented by the formula(1), wherein R1 is C1-C4 linear or branched alkyl group, hydroxy group, a C2-C6 alkylamino group, a 4-sulfamoylphenyl group, or a saturated or unsaturated 5 or 6 membered hetero cycle having 1-2 of hetero atoms selected from N, O and S; R2 is H or a C1-C3 linear or branched alkyl group; or R1 and R2 are bound together with 1-2 of hetero atoms selected from N, O and S to form a saturated or unsaturated 5, 6 or 7 membered hetero cycle, wherein the hetero cycle is a C1-C4 linear or branched alkyl group, or substituted or unsubstituted with a C1-C3 hydroxyalkyl group; and R3 is a 5-indazolyl group; and n is an integer of 0-4.
    • 目的:提供对HBV和HCV的生长抑制优异的新型2,4-二氟苯甲酰胺衍生物,因此用作HBV肝炎和HCV肝炎的预防和治疗剂。 还提供了它们的药学上可接受的盐及其制造方法。 构成:2,4-二氟苯甲酰胺衍生物由式(1)表示,其中R1是C1-C4直链或支链烷基,羟基,C2-C6烷基氨基,4-氨磺酰基苯基或饱和或 具有1-2个选自N,O和S的杂原子的不饱和5或6元杂环; R2是H或C1-C3直链或支链烷基; 或R 1和R 2与1-2个选自N,O和S的杂原子结合在一起以形成饱和或不饱和的5,6或7元杂环,其中杂环是C 1 -C 4直链或支链烷基 或者被C1-C3羟烷基取代或未取代; 并且R 3是5-吲唑基; n为0-4的整数。
    • 9. 发明公开
    • 복합 추출물을 포함하는 배뇨 장애 예방, 치료 및 개선용 조성물
    • 用于预防,治疗和改善包括多种提取物的排尿困难的组合物
    • KR1020170036883A
    • 2017-04-03
    • KR1020150132594
    • 2015-09-18
    • 동화약품주식회사
    • 박다애장윤영김광현이상호전찬석이현용
    • A61K36/67A61K36/62A61K36/8962A61K36/42A61K36/076A61K36/79A61K36/43A23L1/30
    • 본발명은필발(Piper Longum L.) 추출물, 및검인, 구자, 남과인, 복령, 오미자, 오약, 토사자및 호장근으로이루어진군에서선택된 1종이상의추출물을유효성분으로포함하는배뇨장애예방또는치료용약학적조성물및 배뇨장애예방또는개선용건강기능식품에관한것이다. 본발명의복합추출물은천연추출물로인체에무해할뿐만아니라배뇨장애에관여하는다양한기전에동시에관여함으로써배뇨간격을증가시키고, 배뇨압을감소시키고방광의용적을증가시키며, 배뇨근의수축을억제하고배뇨근의이완을유도할수 있고, 특히추출물의복합에따른현저한시너지효과를가져, 다양한배뇨장애를예방, 치료또는개선하는효과가우수하다.
    • 本发明pilbal(荜茇L.)提取物,和树胶,JA,南,预防或治疗排尿困难包括在从由茯苓,五味子,ohyak,tosaja和肌肉号作为活性成分组成的组中选择的提取物 并且涉及用于预防或改善排尿困难的保健功能食品。 的本发明的增加不仅有害于人体作为通过涉及多种参与泌尿疾病机制的同时排尿间隔的天然提取物合并的萃取物,减少排尿压力和增加膀胱的容量,并抑制逼尿肌的收缩 并可能导致逼尿肌舒张,特别是,取提取物的复合物的显著协同作用,其具有优异的预防,治疗或改善各种泌尿疾病的效果。